Advertisement

Response to “Letter to the Editor of Radiotherapy and Oncology regarding the paper titled “MRI and FUNDUS image fusion for improved ocular biometry in Ocular Proton Therapy” by Via et al.”

      We would like to thank Dr. Beenakker and Dr. Rasch for their interest [
      • Beenakker J.
      • Rasch C.
      Letter to the Editor of Radiotherapy and Oncology regarding the paper titled “MRI and FUNDUS image fusion for improved ocular biometry in Ocular Proton Therapy” by Via et al.
      ] in our recent publication [
      • Via R.
      • Pica A.
      • Antonioli L.
      • Paganelli C.
      • Fattori G.
      • Spaccapaniccia C.
      • et al.
      MRI and FUNDUS image fusion for improved ocular biometry in Ocular Proton Therapy.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Beenakker J.
        • Rasch C.
        Letter to the Editor of Radiotherapy and Oncology regarding the paper titled “MRI and FUNDUS image fusion for improved ocular biometry in Ocular Proton Therapy” by Via et al.
        Radiother Oncol. 2022;
        • Via R.
        • Pica A.
        • Antonioli L.
        • Paganelli C.
        • Fattori G.
        • Spaccapaniccia C.
        • et al.
        MRI and FUNDUS image fusion for improved ocular biometry in Ocular Proton Therapy.
        Radiother Oncol. 2022; 174: 16-22
        • Via R.
        • Hennings F.
        • Pica A.
        • Fattori G.
        • Beer J.
        • Peroni M.
        • et al.
        Potential and pitfalls of 1.5T MRI imaging for target volume definition in ocular proton therapy.
        Radiother Oncol. 2020; 154: 53-59
        • Daftari I.K.
        • Aghaian E.
        • O'Brien J.M.
        • Dillon W.
        • Phillips T.L.
        3D MRI-based tumor delineation of ocular melanoma and its comparison with conventional techniques.
        Med Phys. 2005; 32: 3355-3362
        • Marnitz S.
        • Cordini D.
        • Bendl R.
        • Lemke A.
        • Heufelder J.
        • Simiantonakis I.
        • et al.
        Proton therapy of uveal melanomas.
        Strahlentherapie und Onkologie. 2006; 182: 395-399
        • Ferreira T.
        • Jaarsma-Coes M.
        • Marinkovic M.
        • Verbist B.
        • Verdijk R.
        • Jager M.
        • et al.
        MR imaging charachteristics of uveal melanoma whi histopathological validation.
        Neuroradiology. 2022; 64: 171-184
        • Jaarsma-Coes M.
        • Ferreira T.
        • Marinkovic M.
        • Khanh Vu T.
        • van Vught L.
        • van Haren G.
        • et al.
        Comparison of MRI-based and conventional measurement for proton beam therapy of uveal melanoma.
        Ophtalmol Retina. 2022;
        • Tang M.
        • Jaarsma-Coes M.
        • Ferreira T.
        • Zwirs-Grech Fonk L.
        • Marinkovic M.
        • Luyten G.
        A comparison of 3T and 7T MRI for the Clinical Evaluation of Uveal Melanoma.
        J Magn Reson Imag. 2022; 55: 1504-1515

      Linked Article